---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-25-000031"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:17:08.205396+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Supernus Q1 2025: Qelbree sales +44% to $64.7M; ONAPGO launched; total revenue +4% to $149.8M

## Summary
- First quarter 2025 total revenue $149.8M, up 4% YoY; operating loss $(10.3)M vs $(3.2)M in prior year.
- Qelbree net sales $64.7M (+44% YoY); GOCOVRI net sales $30.7M (+16% YoY).
- ONAPGO (apomorphine infusion) launched in U.S. in April 2025 for Parkinson's motor fluctuations.
- Adjusted operating earnings (non-GAAP) increased 16% to $25.9M; full year 2025 guidance reaffirmed.
- Qelbree prescriptions grew 22%; March 2025 monthly Rx hit all-time high of 75,277.

## SEC filing metadata
- accession: 0001356576-25-000031
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000031/0001356576-25-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000031/supn-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-25-000031
- JSON: https://secwatch.observer/filing/0001356576-25-000031.json
- Plain text: https://secwatch.observer/filing/0001356576-25-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.